FIELD: medicine.
SUBSTANCE: pedicle skin flap survival is corrected in laboratory animals is corrected by modelling a flap on the second experimental day. On the first and fourth day of the experiment, nicorandyl is introduced intraperitoneally in a daily dose of 1.3 mg/kg in two stages.
EFFECT: higher skin flap survival in the reduced blood circulation environment ensured by opening the ATP-dependent potassium channels and providing the nitrate-like effect of nicorandyl in the specific experimental environment.
1 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH MINOXIDIL | 2012 |
|
RU2497201C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH L-NORVALINE | 2012 |
|
RU2513619C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH SILDENAFIL | 2012 |
|
RU2498414C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH RESVERATROL | 2012 |
|
RU2511061C1 |
METHOD FOR INCREASING SKIN GRAFT SURVIVAL IN REDUCED CIRCULATION ENVIRONMENT WITH USE OF DIHYDROQUERCETIN | 2014 |
|
RU2547786C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF SKELETAL MUSCLE ISCHEMIA WITH NICORANDYL | 2012 |
|
RU2507597C2 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIC TISSUES SURVIVAL RATE IN REDUCED BLOOD CIRCULATION ENVIRONMENT | 2010 |
|
RU2438190C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIA OF SKELETAL MUSCLE WITH RESVERATROL | 2012 |
|
RU2518965C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF SKELETAL MUSCLE ISCHEMIA WITH L-NORVALINE | 2012 |
|
RU2507596C1 |
METHOD FOR PREVENTION OF ISCHEMIA OF RETINA EXPERIMENTALLY | 2013 |
|
RU2539630C1 |
Authors
Dates
2014-02-20—Published
2012-06-09—Filed